Renal Caps | Renal Caps

07:03 EDT 4th May 2015 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Renal Caps are opaque black oval softgels imprinted "C 162".  These softgels provide water-soluble vitaminsRenal Caps contain the following inactive ingredients: Blue 1 Lake, gelatin, glycerin, lecithin, Red 40 Lake, soybean oil, starch, titanium dioxide, Yellow # 6 Lake, yellow beeswax.

Each softgel contains:

Vitamin C (ascorbic acid)........................100 mg

Thiamine (as thiamine mononitrate)..........1.5 mg

Riboflavin...............................................1.7 mg

Niacin (as niacinamide).............................20 mg

Vitamin B (as pyridoxine HCl)...................10 mg

Folate (folic acid).........................................1mg

Vitamin B (as cyanocobalamin)...............6 mcg

Biotin....................................................150 mcg

Pantothenic Acid (as calcium pantothenate)..5 mg

Renal Caps is indicated in the wasting syndrome of chronic renal failure; uremia and impaired metabolic functions of the kidney.  Renal Caps ia also highly effective as a stress vitamin.

Folic acid may mask the symptoms of pernicious anemia in that hematologic remission may occur while neurological manifestations progress.

One softgel daily, or as directed by physician.  If on dialysis, take after treatment.

Store at controlled room temperature 15-30 C (59-86F).  Keep container tightly closed and protected from heat and moisture.

KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.

Manufactured for Cypress Pharmaceutical, Inc.

Madison, MS  39110

L404 Rev 6/02

NDC 60258-162-01

Renal Caps

Dialysis/ Stress

Vitamin Supplement

Rx Only

Cypress Pharmaceutical, Inc.

100 Softgels

Manufacturer

Cypress Pharmaceutical, Inc.

Active Ingredients

Source

Clinical Trials [1571 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

To date there are no approved effective therapies for the treatment of cryopyrin-associated periodic syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells...

Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy

Patients routinely receive sedation during a colonoscopy or upper endoscopy (esophagogastroduodenoscopy; EGD) procedure. Propofol is a sedative that can be used during these procedures. T...

Community Central Line Infection Prevention Trial

The overall goal of this Community Central Line Infection Prevention (CCLIP) trial, supported by grant R01 HS022870 from the Agency for Healthcare Research and Quality, is to determine whe...

Reducing Distress and Improving Self-Care in Diabetes

To date, there have been few practical, evidenced based interventions that are directed at patients with Type II Diabetes who are experiencing depressed and/or emotional distress in primar...

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohn's disease who have not responded to previous treatment with a grou...

PubMed Articles [2975 Associated PubMed Articles listed on BioPortfolio]

CAPS-1 promotes fusion competence of stationary dense-core vesicles in presynaptic terminals of mammalian neurons.

Neuropeptides released from dense-core vesicles (DCVs) modulate neuronal activity, but the molecules driving DCV secretion in mammalian neurons are largely unknown. We studied the role of calcium-acti...

Nematic caps on colloidal particles in a nematogenic liquid under an electric field.

We examine the localized nematic regions (caps) on spherical colloidal particles suspended in a nematogenic liquid in the isotropic phase in the bulk by solving the Poisson equation with an orientatio...

Exploring plasmonic coupling in hole-cap arrays.

The plasmonic coupling between gold caps and holes in thin films was investigated experimentally and through finite-difference time-domain (FDTD) calculations. Sparse colloidal lithography combined wi...

A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants.

Cryopyrin-associated periodic syndromes (CAPS) are characterized by recurrent episodes of systemic inflammation caused by mutations in the NLRP3 gene. Besides confirmed pathogenic NLRP3 mutations, pat...

Novel layered crystalline organic polymer-inorganic hybrid material comprising calcium phosphate with unique architectures for superior performance catalyst support.

An organic copolymer-inorganic hybrid material, calcium phosphonate-phosphate (CaPS-PVPA), is fabricated under mild conditions. In particular, CaPS-PVPA is not prepared with traditional methods such a...

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Top five promising drugs Phase I (November 2013)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE I TRIALS Drug Disease Company ARC-520 Hepatitis B virus infection Arrowhead Research GR-MD-02 Non-alcoholic steatohepatitis ...

Advertisement

Drugs and Medication Quicklinks


Searches Linking to this Drug Record